We enhance health by modulating communications between cells

At Libera we aim to change the course of an ongoing pathological pathway by introducing new messages thereafter modulating the conversations between the cells involved.


Extracellular vesicles can be used to change the behavior of diseased cells

• Extracellular vesicles carry a complex array of signals, constituting a  peculiar mode of communication between cells

• The tone and content of these at-distance inter-cellular conversations determine the course of physiological and pathological processes

• By artificially including the appropriate message into vesicles, we can change the behavior of inflamed or diseased cells, bringing them back to health


We share the need to bring innovative solutions to inflammatory diseases

Across the world, mortality can be linked to a shared pathway: Systemic Chronic Inflammation. When we communicate effectively with implicated cells, this inflammatory process can be halted – offering restoration and hope for the function of organs at risk.

• Cancer 

• Cardiovascular diseases

• Liver inflammatory diseases

• Neurodegenerative diseases

• Aging


Tackling inflammation with tiny messengers

A platform for innovative biological therapies based on engineered extracellular vesicles (EV) to treat chronic inflammatory diseases.

We are designing customized EV that carry different anti-inflammatory molecules (proteins, RNAs, Lipids) able to target specific organs and cell types to which they transfer their cellular cargoes.


Allows specifically targeting “inflamed” cells, reducing non-desired effects on healthy cells.


It inhibits multiple inflammatory molecules and pathways simultaneously, increasing the chances of therapeutic success.


Matias Ostrowski, DVM, PhD, is an independent researcher at CONICET and a specialist in Extracellular Vesicles biology. His research performed during the last 15 years contributed to our understanding of the biogenesis of Extracellular Vesicles and their functionality in different physiological and pathological contexts, in particular during HIV infection.

Diego Croci, PhD, Associate Researcher at CONICET. Head of Laboratory of Glycobiology and Vascular Biology at IHEM-Mendoza and Associate Professor of glycobiology at the National University of Cuyo UNCUYO. With +20 years’ experience in basic research, he has a wide-ranged background in tumor biology, glycobiology, and Stem cell Biology, with specific training and expertise in neovascularization.

 Juan Pablo Cerliani, biotechnologist with a PhD in cellular biology. Former Adjunct Investigator at CONICET with a strong scientific and medical background, he is currently Medical Science Liaison at AstraZeneca (Oncology department). His career goal is to incorporate and apply biomedical knowledge and Innovative biotechnology tools to improve patients health and quality of life.

Paula Soledad Perez, PhD and Teaching Assistant of Virology at the University of Buenos Aires, has +10 years’ research experience in the fields of Virology, Molecular and Cellular Biology and Immunology. In the last years, she studied the role played by extracellular vesicles in the modulation of inflammation. Her main career goal is to contribute to prevention, diagnosis and treatment of people, thinking about bioscience from a translational point of view.

Nadia Bannoud Medical Doctor, Educational Specialist and PhD in Biological Sciences. She is currently working at Facultad de Ciencias Médicas – Universidad Nacional de Cuyo as researcher in the areas of oncology, angiogenesis and glycobiology, and as a Teaching Assistant Professor in the Physiology Institute. Her main interest is to contribute to biomedical knowledge by improving academic research, aiming at translating it to clinical applications.

Bsc. In Economics, Universidad Católica Argentina. Partner, Finvest Group, oversees investments in Biotech and Healthcare through Securitas Biosciences Group, a venture building fund.
Mr. Vidal led the formation and organization of Securitas Biosciences and attracted key human resources; a diverse interdisciplinary group of scientists, doctors and executives. In 2013, co-founded Finvest’s group first initiative in the biotech sector, VirTech Bio, and led the company as CEO until August 2019. He is acting CEO of Vaxinz, a biotech start-up that specializes in the design and development of novel vaccines targeting human emerging infectious diseases. He serves as Board member and Executive Chairman of several portfolio companies, VirTech Bio, TheraVax, Meton, OCC Biotech and HZ4 Liver.
He has an extensive international career, with over 25 years experience in consulting, Investment Banking, M&A, and portfolio management.
Former Cooper&Lybrand, Deutsche Morgan Grenfell, Dresdner Kleinwort Wasserstein

Juián Maggini is an MD PhD from the University of Buenos Aires, Argentina. Dr. Maggini has specialized in internal medicine at the Austral University Hospital and completed his doctoral thesis at the National Academy of Medicine studying the immunological role of mesenchymal stem cells. He has collaborated in the foundation of the cell culture platform in the Department of Pharmacology of the Faculty of Medicine, University of Buenos Aires. He participated in the creation of the General Direction of Science and Technology Policy Management in the City of Buenos Aires, as an advisor to the General Director. He also worked as Medical Director of the Laboratorio Internacional Argentino and Abbott EPD. Since 2015, Dr. Maggini is the Director of the Technology Transfer Office of the Austral University, which articulates the University, the University Hospital and the Austral Technology Business Park – based companies to promote scientific projects of high impact. The strategy of the TTO is to develop demand-oriented Science & Technology platforms, working collaboratively with technology-based companies as strategic partners. We aim to achieve the sustainability of our R&D portfolio and create an innovation ecosystem based on scientific knowledge.

Senior Analyst at Finvest, responsible for leading the market analysis and the identification of investment opportunities. Responsible for developing a platform thesis for regional healthcare networks (encompassing hospitals, specialized clinics and adjacent business opportunities) in Brazil as well as monitoring and providing management support to portfolio companies. Augusto holds a M.Sc. in Economics from Sao Paulo School of Economics (FGV), B.S. in Economics from the same institution and a B.S. in Physics from USP.

Victoria Sundblad, MSc., PhD. She graduated from the University of Buenos Aires (2000) and has a PhD in Biological Chemistry from the same University (2005). She has more than 20 years of experience in basic biomedical research at CONICET, in the field of molecular endocrinology and immunology. Convinced of the richness of interdisciplinary work and with great ability to alchemize different points of view, she promoted and participated in numerous collaborative projects seeking to contribute to bridging the gap between knowledge and improvement of human health.

B.S. in Administration from University of Buenos Aires. Attend M.Sc. In data science Austral University.Operations Director of the Institute of Applied Artificial Intelligence and member of Technology Transfer, Universidad Austral.

Bioengineer, Technological Institute of Buenos Aires (ITBA). 3+ years working on bioinformatic field and AI. Areas of research include hybrid promoters, synthetic promoters and activated pathways applied on cancer therapies. Alphafold and data processing on Cryo-Em are the current developed areas. 2+ years teaching at ITBA University in the Department of ‘Biomedical Instrumentation II’.

PhD in Biological Sciences with 16+ years of research experience, and translational biotechnology applications, mainly at the Plant Molecular Biology Lab at Fundación Instituto Leloir. My background includes the areas of Molecular Biology, Plant Biology, Cell Biology, and Small Eukaryotes Biology, Biotechnology. Proficient in experimental design, DNA construction design and assembly, transgenesis, RNA and protein expression assays, Protein and other macromolecules purification, Chemical screenings in biological systems, statistical analysis, and biological interpretation. I am very communicative and collaborative, which allows me to establish several interactions and collaborations.

Medical doctor graduated from the University of Buenos Aires (1995) with a specialization in internal medicine and clinical pharmacology. He has been department director and full professor of Human Physiology and currently full professor of the research department at the University Institute of the Italian Hospital of Buenos Aires. He has been a consultant on drug policies for the United Nations and on research management for the Pan American Health Organization. He currently serves as Head of the Clinical Pharmacology Section and Coordinator of the Research Department of the Italian Hospital of Buenos Aires. His area of ​​expertise is clinical studies, particularly phase 1 (first in human).

Mariano Nuñez, is an MD graduated from the University of Buenos Aires, Argentina. He has specialized in Internal Medicine and Pharmacology. He is currently Professor of Pharmacology at the University of Buenos Aires and Director of Pharmacovigilance at the Institute of Pharmacology, School of Medicine, University of Buenos Aires. He has worked as an advisor in the Ministry of Health of Argentina, and has worked as a scientific director in pharmaceutical companies. He is currently general manager of Tecnología Innovativa, a company dedicated to providing global business development services to the pharmaceutical industry, and has participated in the development of several cooperation agreements between global and local companies for business and project development.


Shopping Basket